New investors pump $30m into Cellnovo's mobile diabetes management
This article was originally published in Clinica
Executive Summary
Cellnovo, a UK company developing what it claims is the first mobile diabetes management system, has raised £30m ($48.4m) in a series B financing round. The round was led by Edmond de Rothschild Investment Partners, and marks the first UK investment made by French private equity firm. Other participants in the fundraising include new investors Forbion Capital Partners, Auriga Partners, NBGI Ventures and Crédit Agricole Private Equity, as well as Cellnovo's existing shareholders.